Revolution Medicines Inc.
Revolution Medicines Announces Positive Phase 3 Trial Results for Daraxonrasib in PDAC
Summary
Revolution Medicines, Inc. reported topline results from its Phase 3 RASolute 302 clinical trial, showing that daraxonrasib significantly improved progression-free survival and overall survival in patients with metastatic PDAC compared to standard chemotherapy. The drug demonstrated a median overall survival of 13.2 months versus 6.7 months for chemotherapy, with a hazard ratio of 0.40 (p < 0.0001). The company plans to submit these results to global regulatory authorities, including the FDA, as part of a future New Drug Application.
Profitelligence Alerts
Get alerts for RVMD
Be first to know when Revolution Medicines Inc. files with the SEC.
Filing Categories
Advertisement
About Revolution Medicines Inc.
Revolution Medicines Inc. is a biotechnology company primarily focused on the development of targeted therapies for cancer treatment. The company aims to create innovative drugs by leveraging the potential of inhibitors that target specific oncogenic pathways. Revolution Medicines Inc. specializes in synthetic lethal technologies and non-covalent inhibitors to address complex molecular targets found in cancer cells. With a strong emphasis on research and development, it collaborates with academic institutions and partners within the biopharmaceutical industry to advance its pipeline of drug candidates. Revolution Medicines Inc. is significantly involved in the oncology sector, with potential impacts on patient care through its commitment to developing precision medicines. As a key player in the biotech landscape, the company contributes to the ongoing evolution of cancer treatment methodologies, seeking to extend and improve patients' lives through state-of-the-art therapeutic options.
Official SEC Documents
Advertisement